Determinants of overall survival (OS) of elderly patients with multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017.

• DOI: 10.1200/jco.2023.41.16_suppl.e20035
• Publication Date: 2023-06-04T16:12:40Z
• Authors: Chakra Pani Chaul...; Ludovic Saba; Hong Liang; Barbara Dominguez; Chieh Lin Fu
• Keywords: Regimen

e20035 Background: The survival of older adults with multiple myeloma (MM) continues to improve due advancements in therapy but there is limited real-world data around the outcome elderly (≥ 75 years old) MM patients. These patients are at risk comorbidities, frailty and potential for reduced tolerance treatment. In this IRB approved retrospective analysis, NCDB was used evaluate 30-day mortality determinants overall (OS) who were treated commission on cancer (CoC) accredited facilities across USA. Methods: Using NCDB, we identified N = 54,766 ≥ old diagnosed from 2004 2017. Multivariable cox regression analysis backward elimination utilized identify independent factors, using significance level p < 0.05. Kaplan-Meier curves produced, SAS version 9.4 analyze data. Results: Overall median time 23 months; while rates 1, 3, 5-year 61.9%, 38.0%, 23.6%, respectively. method revealed that 10 significant factors including age, sex, race, ethnicity, education level, Charlson-Deyo score, facility type, income, year diagnosis, treatment-regimen. Male more likely die compared female (HR 1.08, 0.0001). Black predicted have less death events White 0.90, addition that, Hispanic ethnicity non-Hispanic 1.16, Subjects non-academic suffer ones received care academic centers 1.15, Patients income $38,000 1.10, 0.0001), $38,000-$47,999 1.06, 0.0011) $48,000-$62,999 1.04, 0.0031) higher $63,000. hematopoietic stem cell transplantation utilization rate 0.1%. 8%. Detailed will be presented. Conclusions: This large shows inferior OS Blacks non-Hispanics. lower economic status those a also had access an facility. strikingly high (8%) elderly. unacceptably could improved by facilitating quality prompt use novel agents. Prospective studies needed address disparity